COVID-19 in heart transplant recipients

Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart t...

Descripción completa

Detalles Bibliográficos
Autores principales: Taghavi, Sepideh, Raffiei Jelodar, Hoda, Rafati, Ali, Naderi, Nasim, Mirtajaddini, Marzieh, Amin, Ahmad, Valizadeh, Leili, Omidvar, Razieh, Kamali, Monireh, Naseh, Soroush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871157/
https://www.ncbi.nlm.nih.gov/pubmed/36699553
http://dx.doi.org/10.34172/jcvtr.2022.31583
Descripción
Sumario:Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.

Ejemplares similares